View Author
cancer prostate tmprs prostate cancer patient fusion expression 2-erg transcript treatment lymph node metastases mutation tumor boorman lymph tmprss 2-erg etv 1 metastase sample survival akt 1 joost 14-12-10 bw.indd e 17k substitution study chapter analysis fgfr 3 mutations tmprss 2 score gleason androgen tumours tumour lymph nodes result prostatectomy nodal gleason score fication level therapy table tissue pathway nodal bladder characteristic outcome signi cancer-speci fic survival sequence node-positive prostate cancer patients substitution prognostic signi ficance overexpression prognostic stage identi metastasi recurrence progression identi fied xenograft pi 3k antigen pik 3ca node-positive prostate cancer response difference herman gene fusions prostate-speci pleckstrin homology domain androgen-regulated obstruction disease gleason score genomic
10 Most Recent Publications
|
Confirmation of the association of TMPRSS2(exon 0):ERG expression and a favorable prognosis of primary prostate cancer
(Article)
Boormans, J.L. Porkka, K. Visakorpi, T. Trapman, J. |
2011-07-01
|
|
No evidence of FGFR3 mutations in prostate cancer
(Article)
Zuiverloon, T.C.M. Boormans, J.L. Trapman, J. Leenders, G.J. van Zwarthoff, E.C. |
2011-05-01
|
|
Prognostic Implications of Important Genetic Alterations in Prostate Cancer
(Doctoral Thesis)
Boormans, J.L. |
2011-02-18
|
|
E17K substitution in AKT1 in prostate cancer
(Article)
Boormans, J.L. Korsten, H. Ziel-van der Made, A.C. Leenders, G.J. van Verhagen, P.C.M.S. Trapman, J. |
2010-05-01
|
|
Expression of the Androgen-Regulated Fusion Gene TMPRSS2-ERG Does Not Predict Response to Endocrine Treatment in Hormone-Naïve, Node-Positive Prostate Cancer
(Article)
Boormans, J.L. Hermans, K.G.L. Made, A.C.J.Z.v.d. Leenders, G.J.H.L. van Wildhagen, M.F. Collette, L.A.J. Schröder, F.H. Trapman, J. Verhagen, P.C.M.S. |
2010-05-01
|
|
Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer
(Article)
Hermans, K.G.L. Boormans, J.L. Gasi, D. Leenders, G.J.H.L. van Jenster, G.W. Verhagen, P.C.M.S. Trapman, J. |
2009-10-15
|
|
Histopathological characteristics of lymph node metastases predict cancer-specific survival in node-positive prostate cancer
(Article)
Boormans, J.L. Wildhagen, M.F. Bangma, C.H. Verhagen, P.C.M.S. Leenders, G.J. van |
2008-12-01
|
|
An activating mutation in AKT1 in human prostate cancer
(Article)
Boormans, J.L. Hermans, K.G.L. Leenders, G.J. van Trapman, J. Verhagen, P.C.M.S. |
2008-12-01
|
|
Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer
(Article)
Hermans, K.G.L. Korput, H.A.G.M. van der Korsten, H. Kraaij, R. Jenster, G.W. Trapman, J. Marion, R. van Wijngaart, D.J. van de Made, A.Z. van der Dits, N.F. Boormans, J.L. Kwast, Th.H. van der Dekken, H. van Bangma, C.H. |
2008-09-15
|
|
Invasively Estimated International Continence Society Obstruction Classification Versus Noninvasively Assessed Bladder Outlet Obstruction Probability in Treatment Recommendation for LUTS Suggestive of BPH
(Article)
Boormans, J.L. Venrooij, G.E.P.M. van Boon, T.A. |
2007-03-01
|
